O. Cantale

发表

Efficacy outcomes and prognostic factors from real-world patients with advanced non-small-cell lung cancer treated with first-line chemoimmunotherapy: The Spinnaker retrospective study.

C. Escriu, A. Addeo, J. Cave, 2022, International immunopharmacology.

International Survey on Frailty Assessment in Patients with Cancer

A. Addeo, G. Maltese, F. Gomes, 2021, The oncologist.

Risk of SARS-CoV2-Related Mortality in Non-Small Cell Lung Cancer Patients Treated with First-Line Immunotherapy Alone or in Combination with Chemotherapy

G. Banna, A. Friedlaender, H. Yusof, 2021, Cancer investigation.

A Comparison Between First-, Second- and Third-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Non-Small-Cell Lung Cancer and Brain Metastases

A. Addeo, G. Banna, A. Cortellini, 2021 .

Three-Dimensional Deep Noninvasive Radiomics for the Prediction of Disease Control in Patients With Metastatic Urothelial Carcinoma treated With Immunotherapy.

A. Addeo, G. Banna, F. Rundo, 2021, Clinical genitourinary cancer.

Therapeutic efficacy of platinum/etoposide regimens in the treatment of advanced poorly differentiated neuroendocrine carcinomas of the lung: A retrospective analysis

V. Adamo, C. Colarossi, F. Esposito, 2023, Frontiers in Endocrinology.

Neutrophil-to-lymphocyte ratio in combination with PD-L1 or lactate dehydrogenase as biomarkers for high PD-L1 non-small cell lung cancer treated with first-line pembrolizumab

D. Galetta, A. Addeo, G. Banna, 2020, Translational lung cancer research.

Role of the Combination of Cyclin-Dependent Kinase Inhibitors (CDKI) and Radiotherapy (RT) in the Treatment of Metastatic Breast Cancer (MBC): Advantages and Risks in Clinical Practice

D. Giuffrida, G. Ferini, P. Fontana, 2021, Frontiers in Oncology.

Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical Outcomes.

M. Filetti, L. Landi, F. Cappuzzo, 2020, Clinical lung cancer.

Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50%

M. Filetti, L. Landi, F. Cappuzzo, 2020, Cancer Immunology, Immunotherapy.

Clinicopathologic correlates of pembrolizumab efficacy in patients with advanced NSCLC and a PD-L1 expression of >= 50%.

M. Filetti, L. Landi, F. Cappuzzo, 2020, medRxiv.

Are anti-PD1 and anti-PD-L1 alike? The non-small-cell lung cancer paradigm

A. Addeo, G. Banna, M. Bersanelli, 2020, Oncology reviews.

Efficacy of Pembrolizumab Monotherapy in Patients With or Without Brain Metastases From Advanced Non–Small Cell Lung Cancer With a PD-L1 Expression ≥50%

D. Galetta, A. Addeo, G. Banna, 2020, Journal of immunotherapy.

Assessing the role of colonic and other anatomical sites uptake by [18F]FDG‐PET/CT and immune‐inflammatory peripheral blood indexes in patients with advanced non‐small cell lung cancer treated with first‐line immune checkpoint inhibitors

S. Novello, T. Venesio, A. Rizzo, 2023, Thoracic cancer.

International Survey on Frailty Assessment in Patients with Cancer

A. Addeo, G. Maltese, F. Gomes, 2022, The oncologist.

First-line immunotherapy in non-small cell lung cancer: how to select and where to go

A. Addeo, R. Kanesvaran, A. Friedlaender, 2023, Expert review of respiratory medicine.